Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Efstathios Kastritis, Despina Fotiou, Foteini Theodorakakou, Irene Solia, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Nikolaos Kanellias, Maria Roussou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 7021.

https://doi.org/10.1182/blood-2024-203941

Published: 2024

Journal Articles

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Ioannis Ntanasis-Stathopoulos, Eirini Katodrytou, Evdoxia Hatjiharissi, Emmanouil Spanoudakis, Vasiliki Douka, Despina Fotiou, Vasiliki Labropoulou, Dimitra Dalampira, Vasiliki Spiliopoulou, Theodosia Papadopoulou, Dimitrios Christoulas, Panagiotis Malandrakis, Anthi Bouchla, Vasiliki Pappa, Efstathios Kastritis, Evangelos Terpos, Meletios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6988.

https://doi.org/10.1182/blood-2024-206900

Published: 2024

Journal Articles

Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Cybord or Daracybord

Brendan Saunders, Foteini Theodorakakou, Benjamin Evans, Samuel Boullt, Despina Fotiou, Meletios Dimopoulos, Efstathios Kastritis, Giada Bianchi

Blood (2024) 144 (Supplement 1): 6882.

https://doi.org/10.1182/blood-2024-204612

Published: 2024

Journal Articles

Bone Disease Burden Does Not Seem to Impact Overall Survival in Newly Diagnosed Patients with Multiple Myeloma - a Detailed Imaging Analysis on 119 Patients

Evangelos Terpos, Vassilis Koutoulidis, Ioannis Ntanasis-Stathopoulos, Stylianos Mavropoulos-Papoudas, Maria Douka, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Lia-Angela Moulopoulos, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 6941.

https://doi.org/10.1182/blood-2024-209786

Published: 2024

Journal Articles

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Ioannis V Kostopoulos, Vasiliki Spiliopoulou, Despina Fotiou, Foteini Theodorakakou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Maria Gavriatopoulou, Ourania Tsitsilonis, Meletios Dimopoulos, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 361.

https://doi.org/10.1182/blood-2024-209826

Published: 2024

Journal Articles

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2024-205481

Published: 2024

Journal Articles

Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma

Ioannis Ntanasis-Stathopoulos, Maria Douka, Vassilis Koutoulidis, Maria Gavriatopoulou, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Irene Solia, Nikolaos Kanellias, Efstathios Kastritis, Meletios Dimopoulos, Evangelos Terpos, Lia-Angela Moulopoulos

Blood (2024) 144 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2024-209797

Published: 2024

Journal Articles

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Blood (2024) 144 (Supplement 1): 1017.

https://doi.org/10.1182/blood-2024-205705

Published: 2024

Journal Articles

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

Blood (2024) 144 (Supplement 1): 1991.

https://doi.org/10.1182/blood-2024-203519

Published: 2024

Journal Articles

Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome

Maria Papatsirou, Christos Kontos, Ioannis Ntanasis-Stathopoulos, Christina Sotiropoulou, Christine-Ivy Liacos, Maria Gavriatopoulou, Margaritis Avgeris, Efstathios Kastritis, Meletios Dimopoulos, Jerome Moreaux, Andreas Scorilas, Evangelos Terpos

Blood (2024) 144 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2024-206812

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Journal Articles

The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations

Eleni Kalafati, Kostantina Taouxi, Ourania Theologi, Nefeli Mavrianou Koutsoukou, Ioannis Kollias, Christine-Ivy Liacos, Alexandra Papadimou, Katerina Chrisostomidou, Maria Gavriatopoulou, Meletios Dimopoulos, Evangelos Terpos, Nicholas P. Anagnou, Efstathios Kastritis, Tina Bagratuni

Blood (2024) 144 (Supplement 1): 1603.

https://doi.org/10.1182/blood-2024-205460

Published: 2024

Journal Articles

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Blood (2024) 144 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2024-207087

Published: 2024

Journal Articles

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Blood (2024) 144 (Supplement 1): 5166.

https://doi.org/10.1182/blood-2024-210518

Published: 2024

Journal Articles

Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia

Philipp Nakov, Daniela Drandi, Lisa Marie Kaiser, Dajana Kaszynski, Alexander Grunenberg, Jasmin Mark, Elke Runge, Meletios Dimopoulos, Efstathios Kastritis, Tina Bagratuni, Christian Buske, Christiane Pott, Simone Ferrero, Mouhamad Khouja

Blood (2024) 144 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2024-204645

Published: 2024

Journal Articles

Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group

Evangelos Terpos, Efstathios Kastritis, Sosana Delimpasi, Maria Kotsopoulou, Konstantina Papathanasiou, Vasiliki Labropoulou, Eirini Katodrytou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Maria Gavriatopoulou, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2024-204707

Published: 2024

Journal Articles

Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Giorgos Psarros, Efstathios Kastritis, Meletios Dimopoulos

Blood (2024) 144 (Supplement 1): 3380.

https://doi.org/10.1182/blood-2024-209915

Published: 2024

Journal Articles

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo, Craig Cole, Cristina Gasparetto, Vania Hungria, Matthew Jenner, Vladimir Vorobyev, Eduardo Yanez Ruiz, Jian Y. Yin, Rao Saleem, Maeva Hellet, Sandrine Macé, Bruno Paiva, Ravi Vij

Blood (2021) 137 (9): 1154–1165.

https://doi.org/10.1182/blood.2020008209

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Blood (2020) 136 (18): 2038–2050.

https://doi.org/10.1182/blood.2020006844

Published: 2020

Includes: Supplemental data

Journal Articles

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Facon, Jae Hoon Lee, Philippe Moreau, Ruben Niesvizky, Meletios Dimopoulos, Roman Hajek, Ludek Pour, Artur Jurczyszyn, Lugui Qiu, Zandra Klippel, Anita Zahlten-Kumeli, Muhtarjan Osman, Bruno Paiva, Jesus San-Miguel

Blood (2019) 133 (18): 1953–1963.

https://doi.org/10.1182/blood-2018-09-874396

Published: 2019

Includes: Supplemental data

NARROW

Comparison of Anti-CD38 Based Quadruplets As Induction Therapy for Newly Diagnosed Multiple Myeloma

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Predictive Value of Free Light Chain Burden in Patients Newly Diagnosed with AL Amyloidosis Treated with Cybord or Daracybord

Bone Disease Burden Does Not Seem to Impact Overall Survival in Newly Diagnosed Patients with Multiple Myeloma - a Detailed Imaging Analysis on 119 Patients

Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study

Depletion of Mature B Cells and of Normal Plasma Cells (PC) behind the Higher Incidence of Infections after Anti-BCMA VS Anti-GPRC5D Bispecific Antibodies (bsAb) in Relapsed Refractory Multiple Myeloma (RRMM)

Early Treatment Response Assessment with Sequential Whole Body Magnetic Resonance Imaging in Patients with Newly Diagnosed Multiple Myeloma

Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants

Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM Patients with One Prior Line of Lenalidomide-Containing Therapy: A Phase 2 Study of the Greek Myeloma Study Group

Circular RNA Profiling Using High-Accuracy Long-Read Nanopore Sequencing of Multiple Myeloma Cell Lines Reveals the Wide Diversity of the Circular Transcriptome

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

The Combined Treatment of Btkis with Venetoclax Exhibits an Enhanced Therapeutic Effect on Waldenström Macroglobulinemia Cells Bearing CXCR4 Mutations

Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study

Long-Term Follow-up of Real-World Teclistamab Therapy for Relapsed/Refractory Multiple Myeloma from the IMWG Immunotherapy Working Group Committee

Determining the Mutational Landscape of Waldenström's Macroglobulinemia By Liquid Biopsy: Results of the Prospective Ecwm-2 Trial of the European Consortium for Waldenström's Macroglobulinemia

Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment: A Phase 2 Study of the Greek Myeloma Study Group

Less Is More: Deciphering the Association between Ocular Adverse Events and Clinical Activity of Belantamab Mafodotin in Multiple Myeloma

Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma

A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only